Skip to main content

Published locations for AHA: Empagliflozin for T2D reduces heart failure endpoints

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. AHA: Empagliflozin for T2D reduces heart failure endpoints

User login

  • Reset your password
  • /content/aha-empagliflozin-t2d-reduces-heart-failure-endpoints
  • /familypracticenews/article/104712/diabetes/aha-empagliflozin-t2d-reduces-heart-failure-endpoints
  • /fedprac/article/104712/diabetes/aha-empagliflozin-t2d-reduces-heart-failure-endpoints
  • /ehospitalistnews/article/104712/diabetes/aha-empagliflozin-t2d-reduces-heart-failure-endpoints
  • /internalmedicinenews/article/104712/diabetes/aha-empagliflozin-t2d-reduces-heart-failure-endpoints
  • /clinicalendocrinologynews/article/104712/diabetes/aha-empagliflozin-t2d-reduces-heart-failure
  • /ecardiologynews/article/104712/diabetes/aha-empagliflozin-t2d-reduces-heart-failure-endpoints
  • /cardiology/article/104712/diabetes/aha-empagliflozin-t2d-reduces-heart-failure-endpoints
  • /endocrinology/article/104712/diabetes/aha-empagliflozin-t2d-reduces-heart-failure-endpoints
  • /internalmedicine/article/104712/diabetes/aha-empagliflozin-t2d-reduces-heart-failure-endpoints
  • /familymedicine/article/104712/diabetes/aha-empagliflozin-t2d-reduces-heart-failure-endpoints
  • /type-2-diabetes-icymi/article/104712/diabetes/aha-empagliflozin-t2d-reduces-heart-failure-endpoints